Thromboxane synthase
| Thromboxane synthase | ||
|---|---|---|
| Properties of human protein | ||
| Mass / length primary structure | 533 amino acids | |
| Secondary to quaternary structure | Monomer, multipass membrane protein | |
| Cofactor | Hamm | |
| Identifier | ||
| Gene names | TBXAS1 ; CYP5A1 | |
| External IDs | ||
| Enzyme classification | ||
| EC, category | 5.3.99.5 , isomerase | |
| Response type | Rearrangement | |
| Substrate | Prostaglandin H2 | |
| Products | Thromboxane A2 | |
| Occurrence | ||
| Homology family | Thromboxane synthase | |
| Parent taxon | Chordates | |
| Orthologue | ||
| human | House mouse | |
| Entrez | 6916 | 21391 |
| Ensemble | ENSG00000059377 | ENSMUSG00000029925 |
| UniProt | P24557 | P36423 |
| Refseq (mRNA) | NM_001061 | NM_011539 |
| Refseq (protein) | NP_001052 | NP_035669 |
| Gene locus | Chr 7: 139.78 - 140.02 Mb | Chr 6: 38.88 - 39.08 Mb |
| PubMed search | 6916 |
21391
|
The thromboxane synthase (txas) is the enzyme that the rearrangement of prostaglandin H2 to thromboxane A2 catalysed . TXAS is produced in chordating . In humans, the enzyme is found in platelets , the lungs , the kidneys , the spleen and in macrophages . The reaction product thromboxane promotes the constriction of blood vessels and is the natural antagonist of prostacyclin . Mutations at TBXAS1 - gene can TXAS- and Thromboxanmangel, as well as a (rare) dysplasia lead.
TXAS is a target in the treatment of chronic inflammatory bowel disease and in the treatment of bladder cancer in order to reduce the amount of chemotherapeutic agents used. TXAS production is also increased in colon cancer and prostate cancer .
Catalyzed reaction
⇒ 
Prostaglandin H2 is rearranged to thromboxane A2. The response is self-regulating.
Individual evidence
- ↑ UniProt P24557
- ↑ Howes LG, James MJ, Florin T, Walker C: Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease . In: Expert Opin Investig Drugs . 16, No. 8, August 2007, pp. 1255-66. doi : 10.1517 / 13543784.16.8.1255 . PMID 17685873 .
- ^ Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, Watson DK: Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents . In: Oncogene . 27, No. 1, January 2008, pp. 55-62. doi : 10.1038 / sj.onc.1210629 . PMID 17603559 .
- ↑ Sakai H, Suzuki T, Takahashi Y, et al : Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2 . In: FEBS Lett . . 580, No. 14, June 2006, pp. 3368-74. doi : 10.1016 / j.febslet.2006.05.007 . PMID 16709411 .
- ↑ Nie D, Che M, Zacharek A, et al : Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility . In: Am. J. Pathol. . 164, No. 2, February 2004, pp. 429-39. PMID 14742249 . PMC 1602253 (free full text).
- ↑ Hall ER, Tuan WM, Venton DL: Production of platelet thromboxane A2 inactivates purified human platelet thromboxane synthase . In: Biochem. J. . 233, No. 3, February 1986, pp. 637-41. PMID 3707514 . PMC 1153079 (free full text).
Web links
- Jassal / D'Eustachio / reactome.org: Thromboxane synthase (CYP5A1) mediates the isomerization of prostaglandin H2 to thromboxane A2